gaining in scope and effectiveness, chemotherapy of brain tumours remains disappointing. Most chemotherapeutic agents do not enter brain tissue readily, and are toxic if injected intrathecally. Methotrexate is an exception since it can safely be injected intrathecally, but it is of only limited potency against brain tumours (Rubin et al, 1966; Norrell and Wilson, 1967; Wilson and Norrell, 1969) . Currently the nitrosourea drugs BCNU and CCNU are receiving clinical trials against brain tumours. These drugs do enter the central nervous system readily but seem to have a beneficial effect in only about 40% of brain tumours (Wilson and Hoshino, 1969; Fewer et al, 1972; Posner and Shapiro, 1975) .
This study was undertaken to explore the possibility of focal diffusion of chemotherapeutic agents directly into brain tumours or the tumour bed over a prolonged period of time. If the method can be shown to be safe and effective, it could be used as postoperative adjunctive therapy, with the device being implanted at the time of primary resection of a Read before the 27th Annual Conference on Engineering in Medicine & Biology, Philadelphia, Penn., 8 October 1974 , and before the New England Neurosurgical Society Meeting, Evergreen Valley, Maine, 7 March 1975. Supported by NIH Grant No. 5-ROI-CA-13897, National Cancer Institute. Accepted 9 November 1976 tumour for long-term diffusion of chemotherapeutic agents.
Methods
In vitro studies of drug diffusion through silastic rubber membranes were done first, using loops of silastic tubing of measured length immersed in testtubes containing water. Quantities of drug diffused were determined for each water bath sample by quantitative spectrophotometry.
The second phase of study consisted of two types of biological testing. In the first of these, drug diffusion was tested against tissue cultures of human glioblastoma. In the second, diffusion was tested against subcutaneously implanted mouse ependymoblastoma. Initial studies have focused on mithramycin, dactinomycin, and oncovin.
A total of 100 tissue culture flasks of human glioblastoma from an established cell line (supplied by Dr Paul Kornblith of the Massachusetts General Hospital) were studied. Before sterilisation, a 7.5 centimetre length of silastic tubing was placed across the bottom of each flask with its ends externalised through sealed openings in the flask walls. Nutrient mixture FlO (HAM) was changed aseptically every other day, and cultures were examined daily for visual semiquantitation of cell death. Although morphological changes usually preceded cell death, actual cell lysis or separation of all cells from the culture flask was taken as the end point of 100 Y kill.
After cultures were well-established, they were challenged by each drug to be tested, either as a single injection directly into the medium, or by filling the silastic tubing to permit slow diffusion. Control flasks with silastic tubing, but no drug, were maintained with each group of flasks tested.
The ependymoblastoma for subcutaneous implantation in CH-3 mice was obtained from a strain maintained by Dr Nicholas Papadakis at the Boston City Hospital. Tumour removed aseptically from a 'reservoir' mouse was mixed four parts tumour: seven parts D5/Ringer's lactate: one part bicillin in a glass tissue homogeniser; 0.25 ml of homogenate was then injected into each flank of all mice. Control mice either had no silastic implants or a unilateral implant containing no drug. Tests of systemic drug toxicity were done with four intraperitoneal injections of one drug at 48 hour intervals. All mice on silastic chemotherapy received bilateral tumour implants, and a unilateral implant of a 2.5 cm length of silastic tubing containing 0.04 ml of the drug and tied closed at both ends. Drug effectiveness was assessed in terms of tumour size after a two week survival.
Results
In vitro studies showed the best rates of diffusion for dactinomycin, mithramycin, and oncovin, while least satisfactory diffusion was observed with bleomycin, fluorouracil, and thiotepa.
MITHRAMYCIN STUDIES
Twenty tissue culture flasks served as controls of various types, both with and without silastic tubing containing no active drug. In these controls, colonies could be maintained for three to four weeks. Mithramycin directly injected into the medium caused cell death in two to four days at concentrations as low as 0.01 [Lg.ml-1 final dilution (Fig. 1) . Mithramycin diffusion into the flasks through silastic rubber tubules proved disappointing when tissue culture medium changes were continued every other day, even with increased drug concentrations. Such medium changes resulted in an interrupted accumulation of mithramycin in the medium. It was possible to demonstrate a more striking antitumour effect by obviating the washout of mithramycin from the culture medium. This was accomplished by parallel diffusion of mithramycin into a reservoir of stock culture medium at the same time as diffusion was being carried out in the tissue culture flask. With each change of medium, new medium from the diffused flask was introduced so that continuously increasing levels of mithramycin were achieved. unilateral silastic implants containing mithramycin tolerated these devices well. A total of45 mice was studied with bilateral tumour implants and unilateral mithramycin silastic implants. These animals generally tolerated their implantations well with lower drug concentrations, and showed smaller tumour size on the side of the silastic implant with greater drug concentrations, although reduction in tumour growth did not reach statistical significance (p = 0.5).
DACTINOMYCIN STUDIES
Human glioblastoma tissue cultures showed that direct injection produced rapid tumour kills with final drug concentrations as low as 0.002 lig.ml-h (Fig. 2) . With dactinomycin concentrations of 0.5 mg.ml-1 inside the silastic diffusion tubule, disappointingly little effect was obtained by diffusion. With the concentration of dactinomycin increased in the diffusion tubing to 1.0 mg.ml-1, tissue kill levels were improved, with survivals limited to eight to 11 days, even with alternate day changes of fresh culture medium.
In vivo studies of dactinomycin against subcutaneous mouse ependymomas were completed in a series of 121 mice. Calculations on the basis of in vitro data suggest that approximately 6.5 pg of dactinomycin should diffuse through a 25 mm length of silastic tubing over a 14 day planned mouse survival, assuming that in vivo diffusion rates do not differ too greatly from in vitro rates. Intraperitoneal therapy in mice with no tumour with 1.0 and 10.0 lkg doses each administered four times was rather well tolerated. 
Discussion
Semipermeable membranes of silastic rubber have been used in various situations in humans and animals for the slow and prolonged diffusion of a variety of biologically active compounds (Long and Folkman, 1967) . Capsules containing hormones and subcutaneously implanted in animals have been used to prevent ovulation or to prolong lactation over many months (Tatum, 1970) . Urinary bladder catheters have been designed for human use, with antibiotics impregnated into the rubber for slow chronic release over many weeks (Wepsic, 1971) . Experimentally, silastic rubber membranes have been used to induce general anaesthesia through an intravenously implanted loop Folkman and Mark, 1968) . Silastic rubber semipermeable membranes were studied initially in our laboratory, in conjunction with Drs Vernon Mark and Judah Folkman, in the form of 'chemodes' chronically implanted in the brains of experimental animals (Wilkinson et al., 1971 (Wilkinson et al., , 1973 . These devices have been shown to be impenetrable to bacteria and non-toxic to brain tissue. Studies previously performed in our laboratory, and studies in other laboratories, have documented slow diffusion through these membranes of a variety of compounds, including some antitumour drugs (Sehgal et al., 1972; Schmidt et al., 1972; Rosenblum et al., 1973 (Mark et al., 1969) . Animal studies in our laboratory have shown safe diffusion of various agents through intracerebrally implanted silastic capsules, and others have shown similar diffusion of chemotherapeutic agents to be locally effective against subcutaneously implanted mouse tumours (Rosenblum, et al., 1973 
